TARA Protara Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 11, 2026
$2,70
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$2,6252 haftanın en düşüğü
$7,8252 haftanın en yükseği
Piyasa Değeri (MRQ)
$160M
P/E
-2.0
Hisse Başına Kâr
$-1.34
rozetleriniz
52 Haftlık Aralık
$3–$8
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$26
P/E
-2.0
ROE
-33.7%
Net Kâr Marjı
·
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
TARA Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$2.70
Piyasa Değeri (MRQ)
$160M
P/E
-2.0
Hisse Başına Kâr
$-1.34
ROE
-33.7%
52 Haftlık Aralık
$3–$8
TARA Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 10 Ocak 2020 | 1-for-40 | Ters |
Protara Therapeutics, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.
Company History
Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University. Major investors in the company include MPM Capital, Rockhill Partners, TVM Capital, Skyline Ventures, Prism VentureWorks, Vectis Life Sciences and Intersouth Partners. They have invested over $72 million in the company.
The company is led by Timothy Noyes, CEO; Steven Burke, CMO; George Eldridge, CFO; and Scott Toner, director of marketing.
On March 5, 2009, the company announced that it had raised $32 million from its existing investors plus MPM Capital and Vectis Life Sciences. Proteon also announced that it had entered into an option agreement to be acquired by Novartis for up to $550 million. The company went public in 2014.
In September 2019, Proteon Therapeutics merged with ArTara Therapeutics.
PRT-201
Proteon is developing PRT-201 (vonapanitase), a drug to improve blood flow following vascular surgery procedures, and, more broadly, is interested in vascular access for hemodialysis and peripheral arterial disease (PAD). PRT-201 is a recombinant human elastase manufactured for Proteon by Lonza.
In September 2008, the company announced that the Food and Drug Administration had granted fast track status to PRT-201.
In December 2016, they announced that the phase III trial of PRT-201 hadn't reached its primary endpoint, causing Proteon's stock price to drop more than 75%.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar46
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Hisse Başına Kâr$-1.342021-12-31 → 2025-12-31
Serbest Nakit Akışı$-56M2016-12-31 → 2025-12-31
Net kar marjı·2020-12-31 → 2020-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | TARA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | -2.05Y ort. ≈-1.8 | ≈-1.8 | · | · | |
| F/D (MRQ) | 1.05Y ort. ≈0.7 | ≈0.7 | 2.1 | Düşük değerli | |
| Price / FCF (Fiyat / Serbest Nakit Akışı) | -2.65Y ort. ≈-2.8 | ≈-2.8 | · | · | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | -2.65Y ort. ≈-2.8 | ≈-2.8 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 0.75Y ort. ≈0.7 | ≈0.7 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | TARA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| ROA | -29.4%5Y ort. ≈-35.4% | ≈-35.4% | -34.2% | Aynı seviyede | |
| ROE | -33.7%5Y ort. ≈-41.7% | ≈-41.7% | -46.8% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | TARA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 11.05Y ort. ≈15.6 | ≈15.6 | 8.0 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 14.25Y ort. ≈15.3 | ≈15.3 | 7.8 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
12.0%
Sonraki Rapor
Kas 09, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 10, 2026 | $-0.36 | $-0.33 | -8.4% |
| 31 Mart 2026 | $-0.31 | $-0.38 | 18.8% | |
| 31 Aralık 2025 | $-0.37 | $-0.33 | -11.6% | |
| 30 Eylül 2025 | $-0.31 | $-0.39 | 20.9% | |
| 30 Haziran 2025 | $-0.35 | $-0.41 | 15.3% | |
| 31 Mart 2025 | $-0.29 | $-0.46 | 37.1% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| R&D Expense | $43M | $32M | $25M | $17M | $21M | $12M | $4M | $12M | $22M | $19M | $12M | $6M | |
| SG&A Expense | $22M | $17M | $19M | $21M | $26M | $22M | $4M | $10M | $9M | $10M | $8M | $4M | |
| Operating Expenses | $65M | $49M | $44M | $67M | $47M | $34M | $8M | $21M | $30M | $29M | $21M | $11M | |
| Operating Income | $-65M | $-49M | $-44M | $-67M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-8M | |
| Interest Expense | · | · | · | · | $0 | $34.0K | · | · | · | · | · | $857.0K | |
| Interest Income | $6M | $4M | $3M | $1M | $237.0K | $500.0K | · | · | · | · | · | · | |
| Other Non-op | $7M | $5M | $3M | $1M | $237.0K | $466.0K | · | $207.0K | $139.0K | $-14.0K | $-651.0K | $5M | |
| Pretax Income | $57M | $45M | · | · | · | · | $-15M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | $-110.0K | |
| Net Income | $-57M | $-45M | $-40M | $-66M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| EPS (Basic) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · | |
| Shares (Basic) | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | · | · | · | · | · | · | · | · | |
| Shares (Diluted) | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | 11,232,576 | · | · | · | · | · | · | · | |
| EBITDA | $-65M | $-49M | $-44M | $-67M | $-47M | $-34M | $-15M | · | · | $-29M | $-21M | $-8M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50M | $163M | $40M | $24M | $36M | $169M | $564.0K | $19M | $21M | $36M | $40M | $69M | |
| Short-term Investments | $106M | $7M | $26M | $60M | $56M | · | · | $2M | $21M | $5M | $25M | $15M | |
| Prepaid Expense | $4M | $2M | $3M | $2M | $2M | $787.0K | $78.0K | $1M | $1M | $1M | $1M | $1M | |
| Other Current Assets | $65.0K | $2.0K | $37.0K | $127.0K | $34.0K | $52.0K | · | · | · | · | · | · | |
| Current Assets | $160M | $172M | $69M | $86M | $93M | $169M | $764.0K | $23M | $43M | $43M | $67M | $85M | |
| PP&E (Net) | $759.0K | $1M | $1M | $2M | $2M | $1M | $459.0K | $263.0K | $259.0K | $372.0K | $224.0K | $83.0K | |
| PP&E (Gross) | $2M | $2M | $2M | $2M | $2M | $1M | $475.0K | $1M | $971.0K | $937.0K | $665.0K | $467.0K | |
| Accum. Depreciation | $1M | $1M | $824.0K | $483.0K | $236.0K | $119.0K | $16.0K | $827.0K | $712.0K | $565.0K | $441.0K | $384.0K | |
| Goodwill | · | · | · | · | $30M | $30M | · | · | · | · | · | · | |
| Other Non-current Assets | $20.0K | $27.0K | $11.0K | $16.0K | $865.0K | $1M | · | · | $218.0K | $393.0K | $706.0K | $114.0K | |
| Total Assets | $209M | $181M | $79M | $113M | $173M | $203M | $1M | $24M | $44M | $44M | $68M | $85M | |
| Accounts Payable | $3M | $4M | $2M | $2M | $954.0K | $914.0K | $716.0K | $441.0K | $291.0K | $556.0K | $1M | $917.0K | |
| Accrued Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $3M | $3M | $9M | $5M | $3M | $1M | |
| Current Liabilities | $11M | $11M | $6M | $6M | $4M | $3M | $3M | $3M | $9M | $5M | $4M | $2M | |
| Capital Leases | $2M | $3M | $4M | $5M | $6M | $999.0K | · | · | · | · | · | · | |
| Total Liabilities | $13M | $14M | $11M | $11M | $11M | $4M | $3M | $3M | $9M | $5M | $4M | $2M | |
| Common Stock | $54.0K | $35.0K | $11.0K | $11.0K | $11.0K | $11.0K | $3.0K | · | $18.0K | $17.0K | $16.0K | $16.0K | |
| Paid-in Capital | $499M | $412M | $269M | $263M | $256M | $246M | $11M | $209M | $203M | $198M | $195M | $192M | |
| Retained Earnings | $-302M | $-245M | $-200M | $-160M | $-94M | $-47M | $-13M | $-210M | $-190M | $-160M | $-131M | $-110M | |
| AOCI | $90.0K | $2.0K | $-31.0K | $-688.0K | $-211.0K | · | $3.0K | $5.0K | $-14.0K | · | $-11.0K | $-6.0K | |
| Stockholders' Equity | $196M | $167M | $68M | $102M | $162M | $199M | $-2M | $5M | $35M | $38M | $63M | $82M | |
| Liabilities + Equity | $209M | $181M | $79M | $113M | $173M | $203M | $1M | $24M | $44M | $44M | $68M | $85M | |
| Shares Outstanding | 53,587,260 | 35,044,772 | 11,364,903 | 11,267,389 | 11,235,731 | 11,211,840 | 2,627,533 | 481,091 | 17,674,729 | 16,603,559 | 16,501,500 | 16,448,455 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $123.0K | $57.0K | $30.0K | |
| Stock-based Comp | $4M | $4M | $6M | $7M | $10M | $10M | $424.0K | $3M | $3M | $3M | $2M | $459.0K | |
| Deferred Tax | $-11M | $-20M | $-14M | $-9M | $-5M | $-9M | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | $3M | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $1M | $2M | $-7M | |
| Operating Cash Flow | $-56M | $-36M | $-38M | $-26M | $-35M | $-23M | $-5M | $-23M | $-22M | $-24M | $-18M | $-10M | |
| CapEx | $94.0K | $63.0K | $45.0K | $120.0K | $596.0K | $884.0K | $475.0K | $119.0K | $35.0K | $271.0K | $198.0K | $51.0K | |
| Investing Cash Flow | $-139M | $19M | $53M | $15M | $-98M | $3M | $-475.0K | $18M | $-16M | $20M | $-11M | · | |
| Stock Issued | · | · | · | · | · | $74M | · | · | · | · | · | $62M | |
| Stock Repurchased | · | · | $91.0K | $90.0K | $228.0K | · | · | · | · | · | · | · | |
| Net Stock Activity | · | · | $-91.0K | $-90.0K | $-228.0K | $66M | · | · | · | · | · | $62M | |
| Financing Cash Flow | $83M | $140M | $-91.0K | $-90.0K | $-228.0K | $189M | $500.0K | $3M | $23M | $208.0K | $163.0K | · | |
| Net Change in Cash | · | · | · | · | · | · | $-13M | $-2M | $-15M | $-4M | $-29M | $66M | |
| Free Cash Flow | $-56M | $-36M | $-38M | $-27M | $-35M | $-24M | $-16M | · | · | $-24M | $-18M | $-10M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | -7391.4% | · | · | · | · | · | -257.1% | |
| Net Margin | · | · | · | · | · | -7291.4% | · | · | · | · | · | -113.4% | |
| EBITDA Margin | · | · | · | · | · | -7391.4% | · | · | · | · | · | -256.1% | |
| ROA | -29.4% | -34.2% | -42.0% | -46.1% | -25.1% | -33.2% | -98.3% | · | · | -51.4% | -28.1% | -7.4% | |
| ROE | -33.7% | -35.8% | -55.6% | -54.7% | -28.4% | -17.2% | -449.1% | · | · | -56.0% | -29.3% | 37.0% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.6 | 15.7 | 11.2 | 15.0 | 21.7 | 58.1 | 12.0 | · | · | 8.4 | 16.1 | 36.2 | |
| Quick Ratio | 14.2 | 15.5 | 10.7 | 14.7 | 21.2 | 57.8 | 10.6 | · | · | 8.1 | 15.8 | 35.8 | |
| Interest Coverage | · | · | · | · | · | -1013.1 | · | · | · | · | · | -8.8 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | · | · | · | · | · | 0.1 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.67 | $4.77 | $6.01 | $9.06 | $14.41 | $17.77 | $11.46 | · | · | $2.32 | $3.84 | $5.01 | |
| Cash Flow / Share | $-1.32 | $-1.74 | $-3.31 | $-2.35 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.93 | $4.65 | $3.48 | $2.14 | $3.18 | $15.04 | $11.08 | · | · | $2.19 | $2.43 | $4.19 | |
| EPS (TTM) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Net Income TTM | $-57M | $-45M | $-40M | $-66M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| Market Cap | $286M | $185M | $21M | $30M | $76M | $271M | $9M | · | · | $1.26B | $10.24B | $6.84B | |
| P/E | -4.0 | -2.4 | -0.5 | -0.5 | -1.6 | · | · | · | · | · | · | · | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | 2321.1 | |
| P/B | 1.5 | 1.1 | 0.3 | 0.3 | 0.5 | 1.4 | 1.4 | · | · | 32.8 | 161.5 | 83.0 | |
| P / Tangible Book | 1.5 | 1.1 | 0.3 | 0.3 | 0.6 | 1.6 | · | · | · | · | · | · | |
| P / Cash Flow | -5.1 | -5.2 | -0.6 | -1.1 | -2.2 | -11.6 | -0.6 | · | · | -53.3 | -582.8 | -684.9 | |
| P / FCF | -5.1 | -5.2 | -0.6 | -1.1 | -2.2 | -11.2 | -0.6 | · | · | -52.7 | -576.3 | -681.5 | |
| Earnings Yield | -25.1% | -41.1% | -190.4% | -218.7% | -62.4% | · | · | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $17M | $14M | $13M | $10M | $11M | $9M | $9M | $8M | $6M | $8M | $6M | $6M | $7M | $5M | $5M | $3M | |
| SG&A Expense | $6M | $6M | $6M | $5M | $6M | $5M | $5M | $4M | $4M | $4M | $5M | $4M | $5M | $5M | $5M | $5M | |
| Operating Expenses | $23M | $20M | $19M | $15M | $17M | $14M | $14M | $12M | $11M | $12M | $11M | $11M | $12M | $10M | $40M | $8M | |
| Operating Income | $-23M | $-20M | $-19M | $-15M | $-17M | $-14M | $-14M | $-12M | $-11M | $-12M | $-11M | $-11M | $-12M | $-10M | $-40M | $-8M | |
| Interest Income | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $756.0K | $820.0K | $840.0K | $846.0K | $687.0K | $542.0K | $283.0K | |
| Other Non-op | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $756.0K | $820.0K | $840.0K | $846.0K | $687.0K | $542.0K | $283.0K | |
| Net Income | $-22M | $-18M | $-17M | $-13M | $-15M | $-12M | $-13M | $-11M | $-10M | $-11M | $-10M | $-10M | $-11M | $-9M | $-39M | $-8M | |
| EPS (Basic) | $-0.36 | $-0.31 | $-0.39 | $-0.31 | $-0.35 | $-0.29 | $-0.25 | $-0.50 | $-0.45 | $-0.97 | $-0.90 | $-0.87 | $-1.00 | $-0.80 | $-3.46 | $-0.68 | |
| EPS (Diluted) | $-0.36 | $-0.31 | $-0.39 | $-0.31 | $-0.35 | $-0.29 | $-0.25 | $-0.50 | $-0.45 | $-0.97 | $-0.90 | $-0.87 | $-1.00 | $-0.80 | $-3.46 | $-0.68 | |
| Shares (Basic) | 61,006,766 | 57,538,833 | · | 42,272,104 | 42,270,855 | 40,707,937 | · | 22,329,772 | 21,233,163 | 11,420,948 | · | 11,347,887 | 11,307,842 | 11,303,869 | · | 11,265,475 | |
| Shares (Diluted) | 61,006,766 | 57,538,833 | · | 42,272,104 | 42,270,855 | 40,707,937 | · | 22,329,772 | 21,233,163 | 11,420,948 | · | 11,347,887 | 11,307,842 | 11,303,869 | · | 11,265,475 | |
| EBITDA | $-23M | $-20M | · | $-15M | $-17M | $-14M | · | $-12M | $-11M | $-12M | · | $-11M | $-12M | $-10M | · | $-8M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17M | $15M | $50M | $13M | $31M | $91M | $163M | $52M | $90M | $52M | $40M | $34M | $34M | $21M | $24M | $47M | |
| Short-term Investments | $125M | $121M | $106M | $120M | $91M | $33M | $7M | $30M | · | $3M | $26M | $40M | $46M | $66M | $60M | $49M | |
| Prepaid Expense | $4M | $4M | $4M | $3M | $3M | $2M | $2M | $4M | $3M | $3M | $3M | $4M | $4M | $8M | $2M | $2M | |
| Other Current Assets | $230.0K | $17.0K | $65.0K | $218.0K | $78.0K | $16.0K | $2.0K | $3.0K | $4.0K | $3.0K | $37.0K | $2.0K | $1.0K | $127.0K | $127.0K | · | |
| Current Assets | $146M | $140M | $160M | $136M | $125M | $127M | $172M | $85M | $92M | $58M | $69M | $78M | $84M | $95M | $86M | $99M | |
| PP&E (Net) | $1M | $669.0K | $759.0K | $828.0K | $912.0K | $988.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | |
| PP&E (Gross) | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | $824.0K | · | · | · | $483.0K | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $30M | |
| Other Non-current Assets | $74.0K | $76.0K | $20.0K | $21.0K | $29.0K | $35.0K | $27.0K | $33.0K | $19.0K | $31.0K | $11.0K | $3M | $3M | $586.0K | $16.0K | $734.0K | |
| Total Assets | $176M | $192M | $209M | $145M | $157M | $169M | $181M | $94M | $102M | $68M | $79M | $88M | $95M | $106M | $113M | $149M | |
| Accounts Payable | $5M | $4M | $3M | $5M | $5M | $2M | $4M | $2M | $1M | $972.0K | $2M | $3M | $2M | $4M | $2M | $456.0K | |
| Accrued Liabilities | $7M | $4M | $6M | $4M | $3M | $4M | $5M | $5M | $3M | $4M | $3M | $3M | $2M | $1M | $3M | $2M | |
| Current Liabilities | $13M | $9M | $11M | $10M | $10M | $7M | $11M | $9M | $6M | $6M | $6M | $7M | $5M | $6M | $6M | $4M | |
| Capital Leases | $1M | $2M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $6M | |
| Total Liabilities | $15M | $11M | $13M | $12M | $13M | $10M | $14M | $12M | $10M | $10M | $11M | $12M | $10M | $12M | $11M | $9M | |
| Common Stock | $59.0K | $55.0K | $54.0K | $39.0K | $39.0K | $39.0K | $35.0K | $21.0K | $21.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | |
| Paid-in Capital | $503M | $502M | $499M | $417M | $416M | $415M | $412M | $314M | $313M | $270M | $269M | $267M | $266M | $264M | $263M | $261M | |
| Retained Earnings | $-342M | $-320M | $-302M | $-285M | $-272M | $-257M | $-245M | $-232M | $-221M | $-211M | $-200M | $-190M | $-180M | $-169M | $-160M | $-121M | |
| AOCI | $-363.0K | $-364.0K | $90.0K | $143.0K | $77.0K | $89.0K | $2.0K | $29.0K | · | $-1.0K | $-31.0K | $-165.0K | $-336.0K | $-469.0K | $-688.0K | $-1M | |
| Stockholders' Equity | $161M | $181M | $196M | $132M | $144M | $158M | $167M | $82M | $92M | $58M | $68M | $77M | $85M | $95M | $102M | $139M | |
| Liabilities + Equity | $176M | $192M | $209M | $145M | $157M | $169M | $181M | $94M | $102M | $68M | $79M | $88M | $95M | $106M | $113M | $149M | |
| Shares Outstanding | 59,083,935 | 55,055,582 | 53,587,260 | 38,587,260 | 38,581,863 | 38,577,813 | 35,044,772 | 20,629,772 | 11,364,903 | 11,433,837 | 11,364,903 | 11,364,903 | 11,307,962 | 11,306,753 | 11,267,389 | 11,267,389 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $1M | $1M | $1M | $903.0K | $833.0K | $904.0K | $931.0K | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $1M | |
| Operating Cash Flow | $-15M | $-21M | $-17M | $-12M | $-12M | $-15M | $-9M | $-8M | $-8M | $-10M | $-9M | $-7M | $-9M | $-13M | $-5M | $-5M | |
| CapEx | · | · | $24.0K | $4.0K | $22.0K | $44.0K | $0 | $8.0K | · | · | $0 | $37.0K | $2.0K | $6.0K | $6.0K | $83.0K | |
| Investing Cash Flow | $18M | $-15M | $-27M | $-7M | $-48M | $-58M | $22M | $-29M | $3M | $23M | $15M | $6M | $22M | $10M | $-18M | $19M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | $76.0K | · | $27.0K | $0 | $64.0K | $0 | $18.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $-76.0K | · | · | · | $-64.0K | · | · | |
| Financing Cash Flow | $-26.0K | $1M | $81M | $13.0K | $8.0K | $2M | $98M | $0 | $42M | $-76.0K | $0 | $-27.0K | $0 | $-64.0K | $0 | $-18.0K | |
| Free Cash Flow | · | · | · | · | · | $-15M | · | · | · | · | · | · | · | $-13M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1575.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | -1464.0% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -1575.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| ROA | -13.0% | -9.9% | · | -11.1% | -11.6% | -10.1% | · | -12.3% | -9.7% | -12.7% | · | -8.3% | -9.0% | -6.8% | · | -4.7% | |
| ROE | -14.2% | -10.5% | · | -12.4% | -12.7% | -11.0% | · | -14.1% | -10.7% | -14.5% | · | -9.1% | -9.8% | -7.3% | · | -5.0% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 15.7 | · | 13.7 | 12.8 | 18.0 | · | 9.8 | 16.3 | 10.5 | · | 11.5 | 17.1 | 14.8 | · | 26.6 | |
| Quick Ratio | 10.7 | 15.2 | · | 13.4 | 12.5 | 17.7 | · | 9.4 | 15.9 | 10.0 | · | 10.9 | 16.3 | 13.5 | · | 26.0 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.73 | $3.29 | · | $3.43 | $3.74 | $4.11 | · | $3.96 | $8.10 | $5.11 | · | $6.77 | $7.54 | $8.38 | · | $12.35 | |
| Revenue / Share | $0.02 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.37 | · | · | · | $-0.36 | · | · | · | $-0.91 | · | · | · | $-1.14 | · | · | |
| Cash / Share | $0.29 | $0.27 | · | $0.33 | $0.82 | $2.37 | · | $2.51 | $7.88 | $4.57 | · | $2.97 | $3.00 | $1.86 | · | $4.22 | |
| EPS (TTM) | $-1.37 | $-1.36 | · | $-1.20 | $-1.39 | $-1.49 | · | $-2.82 | $-3.19 | $-3.74 | · | $-6.13 | $-5.94 | $-5.70 | · | $-3.31 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-70M | $-63M | · | $-53M | $-51M | $-45M | · | $-42M | $-41M | $-42M | · | $-69M | $-67M | $-64M | · | $-37M | |
| Market Cap | $226M | $287M | · | $168M | $117M | $164M | · | $38M | $24M | $46M | · | $19M | $27M | $35M | · | $33M | |
| P/E | -2.8 | -3.8 | · | -3.6 | -2.2 | -2.9 | · | -0.6 | -0.7 | -1.1 | · | -0.3 | -0.4 | -0.5 | · | -0.9 | |
| P/B | 1.4 | 1.6 | · | 1.3 | 0.8 | 1.0 | · | 0.5 | 0.3 | 0.8 | · | 0.2 | 0.3 | 0.4 | · | 0.2 | |
| P / Tangible Book | 1.4 | 1.6 | · | 1.3 | 0.8 | 1.0 | · | 0.5 | 0.3 | 0.8 | · | 0.2 | 0.3 | 0.4 | · | 0.3 | |
| P / Cash Flow | · | -13.4 | · | · | · | -11.2 | · | · | · | -4.4 | · | · | · | -2.7 | · | · | |
| Earnings Yield | -35.9% | -26.1% | · | -27.6% | -45.9% | -35.0% | · | -154.1% | -153.4% | -93.3% | · | -367.1% | -248.5% | -182.1% | · | -111.8% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Net Gelir | $-57M | $-45M | $-40M | $-66M | $-47M |
| Seyreltilmiş Hisse Başı Kâr | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 14.6 | 15.7 | 11.2 | 15.0 | 21.7 |
| Cari Oran | 14.2 | 15.5 | 10.7 | 14.7 | 21.2 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-56M | $-36M | $-38M | $-27M | $-35M |
Kurumsal Sahipler (13F) 126 dosya · $198.1M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
126
Tutulan Değer
$198.1M
Yeni pozisyonlar
26
Çıkan pozisyonlar
17
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 26 (-6 önceki Ç'ye göre) | 17 (-4 önceki Ç'ye göre) | 50 (+2 önceki Ç'ye göre) | 29 (+5 önceki Ç'ye göre) | -2.1M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | $27.154.562 | 5.207.011 | 13,71% | Hisse senetleri |
| BlackRock, Inc. | $13.994.565 | 3.663.499 | 7,06% | Hisse senetleri |
| VANGUARD GROUP INC | $12.748.844 | 2.391.903 | 6,44% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $11.846.454 | 3.101.166 | 5,98% | Hisse senetleri |
| Velan Capital Investment Management LP | $10.866.571 | 2.844.652 | 5,49% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.786.508 | 2.300.133 | 4,44% | Hisse senetleri |
| Blackstone Inc. | $8.654.263 | 2.265.514 | 4,37% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $8.480.400 | 2.220.000 | 4,28% | Hisse senetleri |
| Sio Capital Management, LLC | $7.341.551 | 1.921.872 | 3,71% | Hisse senetleri |
| ACORN CAPITAL ADVISORS, LLC | $6.693.079 | 1.752.115 | 3,38% | Hisse senetleri |
| Integral Health Asset Management, LLC | $5.730.000 | 1.500.000 | 2,89% | Hisse senetleri |
| 5AM Venture Management, LLC | $5.232.567 | 1.369.782 | 2,64% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $5.067.467 | 1.326.246 | 2,56% | Hisse senetleri |
| CITADEL ADVISORS LLC | $4.707.635 | 1.232.365 | 2,38% | Hisse senetleri |
| STATE STREET CORP | $4.080.887 | 1.068.295 | 2,06% | Hisse senetleri |
| Qube Research & Technologies Ltd | $3.993.871 | 1.045.516 | 2,02% | Hisse senetleri |
| Balyasny Asset Management L.P. | $3.921.960 | 1.026.691 | 1,98% | Hisse senetleri |
| BAKER BROS. ADVISORS LP | $3.711.565 | 971.614 | 1,87% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $3.592.756 | 940.512 | 1,81% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $3.369.924 | 882.179 | 1,70% | Hisse senetleri |
| MARSHALL WACE, LLP | $2.677.900 | 701.021 | 1,35% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $2.611.855 | 683.230 | 1,32% | Hisse senetleri |
| NORTHERN TRUST CORP | $2.109.809 | 552.306 | 1,06% | Hisse senetleri |
| Point72 Asset Management, L.P. | $2.096.920 | 548.932 | 1,06% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $2.086.587 | 546.227 | 1,05% | Hisse senetleri |
| Catalio Capital Management, LP | $1.986.965 | 520.148 | 1,00% | Hisse senetleri |
| MORGAN STANLEY | $1.942.218 | 508.434 | 0,98% | Hisse senetleri |
| Walleye Capital LLC | $1.930.750 | 505.432 | 0,97% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.878.130 | 491.657 | 0,95% | Hisse senetleri |
| UBS Group AG | $1.744.873 | 456.773 | 0,88% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $1.278.489 | 334.683 | 0,65% | Hisse senetleri |
| Verdad Advisers, LP | $1.192.791 | 312.249 | 0,60% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $1.129.058 | 295.565 | 0,57% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $960.730 | 251.500 | 0,48% | Hisse senetleri |
| OPPENHEIMER & CO INC | $910.543 | 238.362 | 0,46% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $798.262 | 208.969 | 0,40% | Hisse senetleri |
| Jump Financial, LLC | $775.842 | 203.100 | 0,39% | Hisse senetleri |
| CIBC WORLD MARKET INC. | $636.011 | 166.495 | 0,32% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $603.449 | 157.971 | 0,30% | Hisse senetleri |
| Bank of New York Mellon Corp | $525.971 | 137.689 | 0,27% | Hisse senetleri |
| J. Goldman & Co LP | $515.700 | 135.000 | 0,26% | Hisse senetleri |
| SUPERSTRING CAPITAL MANAGEMENT LP | $463.966 | 121.457 | 0,23% | Hisse senetleri |
| Fisher Asset Management, LLC | $380.342 | 99.566 | 0,19% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $376.220 | 98.487 | 0,19% | Hisse senetleri |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $325.961 | 85.330 | 0,16% | Hisse senetleri |
| Nuveen, LLC | $277.371 | 72.610 | 0,14% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $266.071 | 69.652 | 0,13% | Hisse senetleri |
| FMR LLC | $260.524 | 68.200 | 0,13% | Hisse senetleri |
| XTX Topco Ltd | $244.281 | 63.948 | 0,12% | Hisse senetleri |
| RHUMBLINE ADVISERS | $241.589 | 63.245 | 0,12% | Hisse senetleri |
Aktivistler ve %5+ sahipler 8 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Deerfield Partners, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., James E. Flynn | 08 Ocak 2021 | · | İlk başvuru | · | SEC |
| Opaleye Management Inc., Opaleye, L.P., James Silverman ×3 başvurular | 25 Eylül 2020 | · | İlk başvuru | · | SEC |
| Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., James E. Flynn ×6 başvurular | 17 Ocak 2020 | · | İlk başvuru | · | SEC |
| Abingworth LLP, Abingworth Bioventures VI, LP | 17 Ocak 2020 | · | İlk başvuru | M&A / satış | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP 98-040-3543 ×3 başvurular | 14 Kasım 2019 | · | İlk başvuru | Yönetim kurulu kampanyası | SEC |
| TVM Life Science Ventures VI L.P., TVM Life Science Ventures VI GmbH & Co. KG, TVM Life Science Ventures Management VI L.P., Hubert Birner, Stefan Fischer, Helmut Schuehsler ×2 başvurular | 02 Ağustos 2017 | · | İlk başvuru | Pasif yatırım | SEC |
| Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Mgmt III, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., James E. Flynn | 29 Haziran 2017 | · | İlk başvuru | Pasif yatırım | SEC |
| Skyline Venture Partners Qualified Purchaser Fund IV, L.P., Skyline Venture Management IV, LLC, John G. Freund, Yasunori Kaneko | 03 Kasım 2014 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 41 içeriden öğrenenler · 16 yöneticiler · 20 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Jesse Shefferman | CEO and President | 29 Haziran 2026 M | 691.832 | 0 | 1 | $-882.160 |
| Timothy P Noyes | President and CEO | 31 Ocak 2019 A | 0 | 0 | 0 | $0 |
| Patrick Fabbio | Chief Financial Officer | 26 Ocak 2026 F | 64.115 | 0 | 0 | $0 |
| Blaine Davis | Chief Financial Officer | 15 Temmuz 2022 F | 20.662 | 0 | 0 | $0 |
| George Arthur Eldridge, | Sr VP, CFO, Treasr, Asst Secy | 18 Ocak 2019 A | 29.132 | 0 | 0 | $0 |
| William Conkling | Chief Commercial Officer | 02 Haziran 2026 F | 69.992 | 0 | 0 | $0 |
| Jacqueline Zummo | Chief R&D Officer | 08 Nisan 2026 S | 94.827 | 0 | 2 | $-124.989 |
| Hannah Fry | VP, Controller | 26 Ocak 2026 F | 42.723 | 0 | 0 | $0 |
| Leonardo Viana Nicacio | Chief Medical Officer | 16 Ocak 2026 A | 78.181 | 0 | 0 | $0 |
| Jathin Bandari | Chief Medical Officer | 19 Ocak 2024 A | 56.704 | 0 | 0 | $0 |
| Julio Casoy | Chief Medical Officer | 09 Ocak 2020 A | 45.500 | 0 | 0 | $0 |
| Steven Keith Burke | SVP and Chief Medical Officer | 15 Mart 2019 G | 26.332 | 0 | 0 | $0 |
| Bradley J Hartman | VP, People | 18 Ocak 2019 A | · | 0 | 0 | $0 |
| Matthew Paul Kowalsky | VP, Legal and Secretary | 18 Ocak 2019 A | 29.479 | 0 | 0 | $0 |
| Scott E. Toner | Senior VP of Commercial | 18 Ocak 2019 A | 23.357 | 0 | 0 | $0 |
| Gottlieb Daniel Philip | VP Corporate Development | 18 Ocak 2019 A | 244 | 0 | 0 | $0 |
| Michael Edward Solomon | Yönetim kurulu üyesi | 15 Haziran 2026 A | 26.500 | 0 | 0 | $0 |
| Jane Huang | Yönetim kurulu üyesi | 15 Haziran 2026 A | · | 0 | 0 | $0 |
| Barry P Flannelly | Yönetim kurulu üyesi | 15 Haziran 2026 A | · | 0 | 0 | $0 |
| Cynthia Smith | Yönetim kurulu üyesi | 15 Haziran 2026 A | · | 0 | 0 | $0 |
| Richard S Levy | Yönetim kurulu üyesi | 15 Haziran 2026 A | 51.000 | 0 | 0 | $0 |
| Roger Garceau | Yönetim kurulu üyesi | 15 Haziran 2026 A | 33.000 | 0 | 0 | $0 |
| Gregory Sargen | Yönetim kurulu üyesi | 15 Haziran 2026 A | 31.000 | 0 | 0 | $0 |
| Luke M Beshar | Yönetim kurulu üyesi | 15 Haziran 2026 A | 198.000 | 0 | 0 | $0 |
| Scott Braunstein | Yönetim kurulu üyesi | 09 Haziran 2020 A | 26.500 | 0 | 0 | $0 |
| John Gordon Freund | Yönetim kurulu üyesi | 08 Kasım 2019 C | 2.175.882 | 0 | 0 | $0 |
| Hubert Birner | Yönetim kurulu üyesi | 08 Haziran 2018 A | 1.943.059 | 0 | 0 | $0 |
| Paul J Hastings | Yönetim kurulu üyesi | 08 Haziran 2018 A | · | 0 | 0 | $0 |
| Scott A Canute | Yönetim kurulu üyesi | 08 Haziran 2018 A | · | 0 | 0 | $0 |
| Garen G Bohlin | Yönetim kurulu üyesi | 08 Haziran 2018 A | 53.312 | 0 | 0 | $0 |
| Jonathan S Leff | Yönetim kurulu üyesi | 08 Haziran 2018 A | · | 0 | 0 | $0 |
| Brendan O'Leary | Yönetim kurulu üyesi | 09 Haziran 2016 A | 1.387.198 | 0 | 0 | $0 |
| Dmitry Kobyzev | Yönetim kurulu üyesi | 02 Haziran 2015 A | 1.165.344 | 0 | 0 | $0 |
| Gregory D Phelps | Yönetim kurulu üyesi | 02 Haziran 2015 A | · | 0 | 0 | $0 |
| Opaleye Management Inc. | 10% sahip | 12 Eylül 2024 S | 45.000 | 0 | 0 | $0 |
| Opaleye, L.P. | 10% sahip | 09 Ocak 2020 A | 2.208.472 | 0 | 0 | $0 |
| Martin Sebastian Olivo | · | 10 Haziran 2021 P | 14.344 | 0 | 0 | $0 |
| Randall Marshall | · | 14 Eylül 2020 S | 585.600 | 0 | 0 | $0 |
| Timothy Haines | · | 12 Kasım 2019 C | 2.144.517 | 0 | 0 | $0 |
| Abingworth LLP | · | 12 Kasım 2019 C | 2.144.517 | 0 | 0 | $0 |
| Stuart A Kingsley | · | 08 Haziran 2018 A | · | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 17 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IWC · iShares Trust | 0,05% | 179.945 SH | 11 Eylül 2026 | Günlük |
| VFMO · VANGUARD WELLINGTON FUND | 0,03% | 141.979 SH | 19 Ağustos 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 300.912 SH | 19 Ağustos 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 45.581 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,01% | 24.988 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 1.339.324 SH | 11 Eylül 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,00% | 125.321 NS | 31 Temmuz 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,00% | 3.715 NS | 31 Temmuz 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,00% | 6.250 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 5.791 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 18.477 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 20.174 NS | 31 Temmuz 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 7.914 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 586.965 SH | 19 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.657.879 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.185 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 472.468 SH | 11 Eylül 2026 | Günlük |
TARA Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 14 analist
AL
Medyan hedef
$26.00
+863,0%
3 21,4%
Güçlü Al
10 71,4%
Al
1 7,1%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
7 analist · 2026-10-01Ortalama hedef $25.71 +852,4%
← Tüm hedeflerin altında
Mevcut fiyat $2.70
Düşük$20.00
Ortalama$25.71
Yüksek$30.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| TARA | $286M | -4.0 | · | · | -33.7% | · |
| DTIL | $100M | -1.2 | -50.1% | -133.4% | -72.4% | · |
| ORGO | $658M | 34.5 | 17.0% | 6.6% | 13.9% | · |
| AVXL | · | -16.5 | -36.1% | -991.4% | · | · |
| ALXO | $61M | -0.6 | · | · | -225.0% | · |
| VYGR | $232M | -1.9 | -49.5% | -296.5% | -54.4% | · |
| PEPG | $448M | -3.1 | · | · | -82.0% | · |
| NERV | $174M | -0.1 | · | · | 339.5% | · |
| NBP | $1.06B | -19.0 | · | · | -21.4% | · |
| CMPX | $958M | · | · | · | -45.9% | · |
| TNXP | $200M | -1.1 | 29.8% | -946.2% | -60.0% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 11, 2026